Crossmark

Assisting the implementation of screening for type 1 diabetes by using artificial intelligence on publicly available data

Crossref DOI link: https://doi.org/10.1007/s00125-024-06089-5

Published Online: 2024-02-14

Published Print: 2024-06

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Teixeira, Pedro F.

Battelino, Tadej https://orcid.org/0000-0002-0273-4732
Carlsson, Anneli

Gudbjörnsdottir, Soffia

Hannelius, Ulf https://orcid.org/0000-0003-1562-437X
von Herrath, Matthias

Knip, Mikael https://orcid.org/0000-0003-0474-0033
Korsgren, Olle https://orcid.org/0000-0002-8524-9547
Elding Larsson, Helena https://orcid.org/0000-0003-3306-1742
Lindqvist, Anton

Ludvigsson, Johnny https://orcid.org/0000-0003-1695-5234
Lundgren, Markus https://orcid.org/0000-0001-6394-7689
Nowak, Christoph https://orcid.org/0000-0001-8435-3978
Pettersson, Paul

Pociot, Flemming https://orcid.org/0000-0003-3274-5448
Sundberg, Frida

Åkesson, Karin https://orcid.org/0000-0003-2556-5094
Lernmark, Åke https://orcid.org/0000-0003-1735-0499
Forsander, Gun https://orcid.org/0000-0002-0266-9651
Funding

Funding for this research was provided by:

VINNOVA (2021-02 684)

Lund University
License Information

Text and Data Mining valid from 2024-02-14

Version of Record valid from 2024-02-14
More Information

Article History

Received: 26 April 2023

Accepted: 6 December 2023

First Online: 14 February 2024

Acknowledgements

: PFT, ÅL and GF would like to thank M. Atkinson (UF Diabetes Institute, University of Florida) and D. Agardh (Lund University) for attending the workshop and providing valuable feedback to the ASSET project. ASSET includes the following partners: Diamyd Medical AB (Stockholm, Sweden), MainlyAI AB (Stockholm, Sweden), Leading Healthcare Foundation (Stockholm, Sweden), Sahlgrenska University Hospital (Gothenburg, Sweden), the National Diabetes Registry (Gothenburg, Sweden) and Lund University (Malmö, Sweden).

: Open access funding provided by Lund University. ASSET is funded by the Swedish Innovation Agency (VINNOVA) through grant 2021-02684.

: PFT, UH, AL and CN are employees of Diamyd Medical AB. PFT, UH and CN own shares in Diamyd Medical AB. ÅL serves on the scientific advisory board of Diamyd Medical AB. PP is a founder and board member of MainlyAI AB. PFT, UH, PP, ÅL, SG, GF and FS are members of the ASSET steering group.

: PFT, ÅL and GF were responsible for drafting the article. All authors critically reviewed the manuscript and approved the version to be published.

Document is current

Any future updates will be listed below